| Drug General Information |
| Drug ID |
D0W7LK
|
| Former ID |
DNC002589
|
| Drug Name |
2-Propanol, Isopropanol
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C3H8O
|
| Canonical SMILES |
CC(C)O
|
| InChI |
1S/C3H8O/c1-3(2)4/h3-4H,1-2H3
|
| InChIKey |
KFZMGEQAYNKOFK-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
4963, 423976, 589444, 813293, 823371, 825349, 826612, 841342, 3135164, 5272310, 6436218, 7847205, 7888433, 7888444, 8006213, 8006303, 8006343, 8006719, 8007054, 8007624, 8007625, 8008177, 8008179, 8008181, 8008185, 8008188, 8008189, 8008222, 8008715, 8008832, 8009929, 8009948, 8010226, 8011055, 8011235, 8011519, 8011800, 8012365, 8013746, 8013748, 8013757, 8014331, 8014403, 8014510, 8014698, 8015403, 8015571, 8016872, 8018534, 8019056
|
| Target and Pathway |
| Target(s) |
Nitric-oxide synthase, endothelial |
Target Info |
Inhibitor |
[1]
|
|---|
| Oxysterols receptor LXR-beta |
Target Info |
Inhibitor |
[1]
|
| Heme oxygenase |
Target Info |
Inhibitor |
[1]
|
|
BioCyc Pathway
|
Citrulline-nitric oxide cyclePWY-5874:Heme degradation
|
|
KEGG Pathway
|
Arginine and proline metabolism
|
|
Metabolic pathways
|
|
Calcium signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
HIF-1 signaling pathway
|
|
Sphingolipid signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
VEGF signaling pathway
|
|
Platelet activation
|
|
Estrogen signaling pathway
|
|
Oxytocin signaling pathwayhsa00860:Porphyrin and chlorophyll metabolism
|
|
Mineral absorption
|
|
MicroRNAs in cancer
|
|
NetPath Pathway
|
Wnt Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
Endothelin signaling pathway
|
|
Interleukin signaling pathway
|
|
PI3 kinase pathway
|
|
VEGF signaling pathway
|
|
Pathway Interaction Database
|
Plasma membrane estrogen receptor signaling
|
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
|
Angiopoietin receptor Tie2-mediated signaling
|
|
Thromboxane A2 receptor signaling
|
|
SHP2 signaling
|
|
VEGFR1 specific signals
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
PAR1-mediated thrombin signaling eventsrxr_vdr_pathway:RXR and RAR heterodimerization with other nuclear receptorfra_pathway:Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
|
HIF-1-alpha transcription factor network
|
|
PathWhiz Pathway
|
Porphyrin Metabolism
|
|
Reactome
|
ROS production in response to bacteria
|
|
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
|
|
eNOS activation
|
|
Nitric oxide stimulates guanylate cyclase
|
|
VEGFR2 mediated vascular permeabilityR-HSA-383280:Nuclear Receptor transcription pathwayR-HSA-917937:Iron uptake and transport
|
|
WikiPathways
|
ACE Inhibitor Pathway
|
|
EGF/EGFR Signaling Pathway
|
|
Myometrial Relaxation and Contraction Pathways
|
|
JAK/STAT
|
|
Corticotropin-releasing hormone
|
|
AGE/RAGE pathway
|
|
Endothelin Pathways
|
|
Leptin signaling pathway
|
|
Effects of Nitric Oxide
|
|
Metabolism of nitric oxide
|
|
AngiogenesisWP1982:SREBP signalling
|
|
Nuclear ReceptorsWP408:Oxidative Stress
|
|
Transcriptional activation by NRF2
|
|
NRF2 pathway
|
|
Nuclear Receptors Meta-Pathway
|
|
miR-targeted genes in squamous cell - TarBase
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in leukocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBase
|
| References |
| REF 1 | How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. |
|---|
